SEC Company Response from GSK (GSK) — May 23, 2013
GSK plc
Date: May 23, 2013 · CIK: 0001131399 · Accession: 0000903423-13-000354
AI Filing Summary & Sentiment
Referenced dates: May 14, 2013
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 United States Re: Comment Letter—GlaxoSmithKline plc (“GSK”) Annual Report on Form 20-F for 2012
Dear Mr. Rosenberg:
We appreciated the opportunity to speak with your colleague Sasha Parikh today in connection with the comment letter dated May 14, 2013 relating to GSK’s Annual Report on Form 20-F for 2012. As requested, this is a brief note to indicate that GSK intends to respond to the comments by June 11, 2013.
The preparation of a response to staff comment letters typically involves a number of GSK business, financial and legal personnel, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Evan Leitch, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Lisa Vanjoske, Securities and Exchange Commission
Ms. Sasha Parikh, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline plc
Ms. Victoria Whyte, GlaxoSmithKline plc
Mr. Ranjan Sriskandan, PricewaterhouseCoopers
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
Writer's Direct Dial: +44 (0) 207 614-2237
E-Mail: ssperber@cgsh.com
May 23, 2013
BY EDGAR
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
United States
Re:
Comment Letter—GlaxoSmithKline plc (“GSK”) Annual Report on Form 20-F for 2012
Dear Mr. Rosenberg:
We appreciated the opportunity to speak with your colleague Sasha Parikh today in connection with the comment letter dated May 14, 2013 relating to GSK’s Annual Report on Form 20-F for 2012. As requested, this is a brief note to indicate that GSK intends to respond to the comments by June 11, 2013.
The preparation of a response to staff comment letters typically involves a number of GSK business, financial and legal personnel, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Evan Leitch, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Lisa Vanjoske, Securities and Exchange Commission
Ms. Sasha Parikh, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline plc
Ms. Victoria Whyte, GlaxoSmithKline plc
Mr. Ranjan Sriskandan, PricewaterhouseCoopers